These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1007 related items for PubMed ID: 30337183
1. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group. Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183 [Abstract] [Full Text] [Related]
2. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators. Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251 [Abstract] [Full Text] [Related]
4. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE. Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M. J Pediatr; 2022 Jan 28; 240():158-163.e4. PubMed ID: 34461064 [Abstract] [Full Text] [Related]
6. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE. Miyata K, Miura M, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H. Circ Cardiovasc Qual Outcomes; 2021 Feb 28; 14(2):e007191. PubMed ID: 33541111 [Abstract] [Full Text] [Related]
8. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease. Nakagama Y, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Oka A. Pediatr Int; 2016 Mar 28; 58(3):180-184. PubMed ID: 26222760 [Abstract] [Full Text] [Related]
13. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T. J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643 [Abstract] [Full Text] [Related]
14. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. Goto M, Miyagawa N, Kikunaga K, Miura M, Hasegawa Y. Endocr J; 2015 Jul 06; 62(2):145-51. PubMed ID: 25342092 [Abstract] [Full Text] [Related]